Results 81 to 90 of about 3,893,535 (160)

Peptide receptor radionuclide therapy for ectopic Cushing’s syndrome caused by metastatic neuroendocrine neoplasms

Endocrine Oncology
Background: Metastatic gastroenteropancreatic neuroendocrine neoplasms (GEPNEN) can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and medical therapy is complex and can be ineffective.
Emma Boehm, Terry Hung, Tim Akhurst, Ramin Alipour, Cherie Chiang, Rodney J Hicks, Michael S Hofman, Aravind S Ravi Kumar, Nirupa Sachithanandan, Javad Saghebi, Michael Michael, Grace Kong   +11 more
doaj   +1 more source

Theranostics in Pancreatic Neuroendocrine Neoplasms: From Molecular Imaging to Personalized Radionuclide Therapy

Radiation
Pancreatic neuroendocrine neoplasms (PanNENs) are a heterogeneous group of tumors characterized by variable biological behavior and frequent overexpression of somatostatin receptors, making them ideal candidates for theranostic approaches.
Takehiro Okabayashi, Ryo Inada, Motoyasu Tabuchi, Rika Yoshimatsu, Yuji Negoro, Akihito Nishioka   +5 more
doaj   +1 more source

177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites

World Journal of Nuclear Medicine, 2017
The present study aimed at exploring the patient and imaging characteristics of primary neuroendocrine tumors (NETs) of rare sites who presented with metastatic and/or advanced inoperable stages and therefore was considered for peptide receptor ...
Pradeep Thapa, Rahul Parghane, Sandip Basu   +2 more
doaj   +1 more source

Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy

Case Reports in Dermatological Medicine
Neuroendocrine neoplasms (NENs) encompass a diverse range of biologically and behaviorally distinct epithelial malignancies that derive from neuroendocrine cells. These neoplasms are able to secrete a variety of bioactive amines or peptide hormones.
Eleanor Tung-Hahn, Ghassan El-Haddad, Jonathan Strosberg   +2 more
doaj   +1 more source

The gastrin-releasing peptide receptor in oncology: a comprehensive review of recent advances in targeted radionuclide theranostics

Frontiers in Oncology
The gastrin-releasing peptide receptor (GRPR) is aberrantly expressed in several malignancies, including prostate cancer, breast cancer, lung cancer, and gastrointestinal stromal tumors, making it an important target for molecular imaging and targeted ...
YunLong Yang, YunLong Yang, Jiang Fu, ShengJie Tang, Tao Liu, HaiYang Hu, HaiYang Guo, Long Wen, Long Wen, Yang Yang, Yang Yang, ChengKuan Liu, ChengKuan Liu, GuiYan Yi, Li Yu, HaiNing Zhou, HaiNing Zhou, HaiNing Zhou, HaiNing Zhou   +18 more
doaj   +1 more source

Peptide receptor radionuclide therapy of neuroendocrine tumours

, 2016
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an
Brabander, Tessa, van Eijck, Casper, de Herder, W.W., Franssen, Gaston, Teunissen, Jaap, Feelders, R.A., Kwekkeboom, Dik   +6 more
core   +1 more source

Tolerability and outcomes of neuroendocrine tumors treated with PRRT and SBRT

Endocrine Oncology
There is interest in optimizing peptide receptor radionuclide therapy (PRRT) for the management of metastatic neuroendocrine neoplasms (NEN). The addition of stereotactic body radiation therapy (SBRT) may provide synergistic benefits by targeting ...
Jose E Nunez, Sylvia Ng, Hanbo Chen, Simron Singh, Julie Hallet, Calvin Law, Sten Myrehaug   +6 more
doaj   +1 more source

Potentially fatal crisis after 177Lu-DOTATATE therapy for paraganglioma: a case report with review of literature

Endocrine Journal
Pheochromocytoma/paraganglioma (PPGL) is a rare neuroendocrine tumor with metastatic potential. Peptide receptor radionuclide therapy with 177Lu-DOTATATE, a radiolabeled somatostatin analog, has been used for the treatment of somatostatin receptor ...
Aoki Tobimatsu, Kosuke Mukai, Yoshinari Obata, Kayako Isohashi, Kazuyuki Miyashita, Atsunori Fukuhara, Hiroki Kato, Iichiro Shimomura   +7 more
doaj   +1 more source

Improvement strategies for peptide receptor scintigraphy and radionuclide therapy

, 2008
Somatostatin receptor-targeting peptides are widely used for the imaging and therapy of neuroendocrine tumors. Peptide-receptor radionuclide therapy (PRRT) in neuroendocrine tumor patients with radiolabeled somatostatin analogs has resulted in ...
Visser, Martijn, Jong, Marion, Verwijnen, SM   +2 more
core   +1 more source

Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy

, 2011
Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC or 177Lu-DOTATATE has demonstrated its efficacy in the treatment of neuroendocrine- and somatostatin-receptor expressing tumours .
Andrea Piccin, Irene Pusceddu, Piccin, Andrea, Sergio Cortelazzo, Chiara Maria Grana, Giovanni Negri, Paganelli, Giovanni, Giovanni Paganelli, Cortelazzo, Sergio, Negri, Giovanni, Grana, Chiara Maria, Pusceddu, Irene   +11 more
core   +1 more source